SNYNF — Sanofi
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1121404 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2027-01-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 15,233,000,000 | 11,601,000,000 | 4,705,000,000 | 3,021,000,000 | 130,287,000,000 | 5,966,000,000 | 57,046,000,000 |
| Jun 2026 | 12,300,000,000 | 9,283,000,000 | 2,384,000,000 | 343,000,000 | 129,060,000,000 | 6,350,000,000 | 59,493,000,000 |
| Mar 2026 | 11,244,000,000 | 8,106,000,000 | 2,269,000,000 | 1,614,000,000 | 128,024,000,000 | 5,544,000,000 | 54,881,000,000 |
| Dec 2025 | 12,205,000,000 | 8,449,000,000 | 1,630,000,000 | -801,000,000 | 126,805,000,000 | 7,657,000,000 | 55,095,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$11,957,000,000
Investing CF
$-4,871,000,000
Financing CF
$-9,615,000,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$3.49
As of
2026-11-08
Yahoo Snapshot (yfinance, live)
Total Revenue
$48,918,999,040
EBITDA
$13,543,000,064
Free Cash Flow
$6,298,999,808
Enterprise Value
$118,247,759,872
Total Cash
$6,350,000,128
Total Debt
$23,576,000,512
Shares Out
1,198,068,685
Trailing EPS
$3.77
Book Value
$67.20
ROE
5.7%
ROA
5.1%
Div Yield
5.76%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,716,000,000 | 9,597,000,000 | 7,813,000,000 | 126,805,000,000 | 55,095,000,000 | 71,376,000,000 | 10,750,000,000 |
| Dec 2024 | 44,286,000,000 | 8,923,000,000 | 5,560,000,000 | 132,798,000,000 | 54,941,000,000 | 77,507,000,000 | 9,081,000,000 |
| Dec 2023 | 41,618,000,000 | 8,691,000,000 | 5,400,000,000 | 126,464,000,000 | 52,111,000,000 | 74,040,000,000 | 10,258,000,000 |
| Dec 2022 | 40,561,000,000 | 10,926,000,000 | 8,371,000,000 | 127,000,000,000 | 51,600,000,000 | 74,784,000,000 | 10,526,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany
2026-11-19 08:30 · Yahoo
Sanofi (ENXTPA:SAN) Wins FDA Approval For First Type 3 Gaucher Brain Therapy
2026-11-19 06:15 · Yahoo
Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
2026-11-19 06:00 · Yahoo
Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
2026-11-18 22:19 · Yahoo
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
2026-11-18 18:10 · Yahoo
Global Medical Countermeasures Market 2026: Size, Trends, and Forecast to 2030 | Capitalize on AI, Stockpiling, and Rapid Diagnostics with Pfizer, Moderna, Sanofi, and Emergent
2026-11-18 14:36 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
2026-11-17 21:12 · Yahoo
Seawolf Therapeutics and Sanofi agree $1.2bn drug deal
2026-11-17 12:15 · Yahoo
Sanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patients
2026-11-16 14:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.